💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Somapacitan

CHEMBL3707290 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
1310.5 g/mol
LogP
-2.1
Phase
4

Somapacitan is a long-acting recombinant human growth hormone analog with a fatty acid conjugate that facilitates reversible albumin binding, extending its half-life to allow once-weekly subcutaneous administration for the treatment of growth hormone deficiency in adults. By mimicking endogenous GH signaling through the GH receptor, it stimulates IGF-1 production, promotes protein anabolism, and improves body composition in GH-deficient patients. Once-weekly dosing offers a significant convenience advantage over daily GH formulations.

Peso Molecular

1310,5000 g/mol

LogP

-2,10

TPSA

544,00 Ų

Regra dos 5 de Lipinski

Reprovado

Mecanismo de Ação

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=C(CCCCCCCCCCCCCCCc1nnn[nH]1)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)N[C@@H](CCCCNC(=O)CSC[C@H](N)C(=O)O)C(N)=O)C(=O)O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C55H97N13O19S2/c1-40(18-13-11-9-7-5-3-2-4-6-8-10-12-14-20-45-64-67-68-65-45)66-89(82,83)35-17-21-46(69)59-27-29-84-32-34-87-37-50(73)63-44(55(80)81)23-25-48(71)62-43(54(78)79)22-24-47(70)60-28-30-85-31-33-86-36-49(72)61-42(52(57)75)19-15-16-26-58-51(74)39-88-38-41(56)53(76)77/h41-44,66H,1-39,56H2,(H2,57,75)(H,58,74)(H,59,69)(H,60,70)(H,61,72)(H,62,71)(H,63,73)(H,76,77)(H,78,79)(H,80,81)(H,64,65,67,68)/t41-,42-,43-,44-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C54H95N13O20S2

                    

                    
                    

                        
HBD / HBA

                        
13 / 25

                    

                    
                    

                        
Ligações Rotacionáveis

                        
59

                    

                    
                    
                    

                        
Átomos Pesados

                        
89

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
Somapacitan is a long-acting recombinant human growth hormone analog with a fatty acid conjugate that facilitates reversible albumin binding, extending its half-life to allow once-weekly subcutaneous administration for the treatment of growth hormone deficiency in adults. By mimicking endogenous GH signaling through the GH receptor, it stimulates IGF-1 production, promotes protein anabolism, and improves body composition in GH-deficient patients. Once-weekly dosing offers a significant convenience advantage over daily GH formulations.

                        

                    

                    

                    

                    
                    

                        
                        

                            
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Somapacitan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3707290.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 129894493.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.